damian.mikulski

MD, PhD
hematologist with a special interest in data science
#myeloma #MM #MMSM

[Noopur Raje @NoopurRajeMD]

Looking @ our future leaders @Myeloma_Society @JoshuaRichterMD @DrKrinaPatel @SurbhiSidanaMD and others.. congratulations!

[damian.mikulski @dmikulskimd]

Honored to receive the Young Investigator Award at #IMS2026 for our study of second primary malignancies after auto-HSCT in multiple myeloma. Grateful to @Transplant_Doc, @Myeloma_Doc and the @MDAndersonNews team. It was a privilege to receive it from @mvmateos. #mmsm

[damian.mikulski @dmikulskimd]

Great to see our #IMS26 study on second primary malignancies featured by @Blood_Cancers Today ! Thank you for highlighting our findings and their implications for the long-term care of patients with myeloma.
https://t.co/mTcjR4zODj

[damian.mikulski @dmikulskimd]

@CoachBon @UTMDAnderson @Transplant_Doc @Myeloma_Doc One reason our estimate is higher than in some earlier reports is that, thanks to more effective myeloma treatments, patients now live much longer after transplantation. This also gives second cancers more time to develop and be diagnosed

[damian.mikulski @dmikulskimd]

At #IMS2026 in Glasgow, I presented our @UTMDAnderson study of 2,419 myeloma pts after auto-HSCT. SPMs occurred in 10.1%: ~1/4 hematologic, ~1/4 NMSC and ~1/2 other solid tumors. New SPMs occurred beyond 10 years, supporting long-term surveillance. @Transplant_Doc @Myeloma_Doc

[damian.mikulski @dmikulskimd]

Only one week until #IMS26!

I am speaking at IMS 2026 in Glasgow this September.
Reserve your spot today to hear my session!

https://t.co/3zdB5G5rcX

[Muzaffar Qazilbash @Transplant_Doc]

Del(13q)/−13 is independently associated with inferior PFS and OS in MM patients undergoing autoHSCT, with an additive adverse effect when co-occurring with HRCA #mms #bmtsm @dmikulskimd #orenpasvolsky @UTMDAnderson https://t.co/zyLWCoAL1S

[damian.mikulski @dmikulskimd]

Delighted to share our new @BrJHaem paper: del(13q)/−13 independently predicted inferior PFS and OS in 1,680 patients with #MultipleMyeloma undergoing upfront autoHCT.

Many thanks to all co-authors, especially @Myeloma_Doc and @Transplant_Doc!

https://t.co/ySZbCJ3L5v

[Robert Z. Orlowski @Myeloma_Doc]

Bonus #Myeloma Paper of the Day from our team @MDAndersonnews: Single cell analysis of tumor microenvironment landscape across myeloma disease spectrum finds 5 reproducible TME ecotypes that have prognostic significance and may help guide therapy: https://t.co/YwDJtZ7F85. #mmsm

[damian.mikulski @dmikulskimd]

@Myeloma_Doc @MDAndersonnews Congratulations to you and the entire team on this excellent publication!

[damian.mikulski @dmikulskimd]

At #EHA2026, we show that combining IMS-IMWG with R2-ISS in 914 transplant-eligible #myeloma pts identifies a distinct intermediate-risk group (standard-risk by IMS-IMWG but with R2-ISS III–IV) not captured by genomic classification alone (PF1122). Disease burden still matters.

[damian.mikulski @dmikulskimd]

Presented at #EHA2026: independent validation of the new IMS–IMWG high-risk classification in 1,193 transplant-eligible #myeloma patients (poster PF777).
The model showed robust prognostic value, with outcomes worsening stepwise as high-risk features accumulated.
#MM #MMSM

[Myeloma Society @Myeloma_Society]

Mark your calendars for the 4th Annual Workshop on Genomics. 📅 July 10-11 in Warsaw, Poland. Register today! https://t.co/Y3I03jsEqJ

[damian.mikulski @dmikulskimd]

Three posters, countless inspiring discussions, and plenty of Swedish sunshine ☀️🇸🇪

Excited to be at #EHA2026 in Stockholm, sharing our work on #myeloma and engaging with colleagues from around the globe. @Transplant_Doc

#MM #MMSM

[damian.mikulski @dmikulskimd]

@Myeloma_Doc Thank you for highlighting our work, Professor @Myeloma_Doc ! Great to see the ATLAS study recognized in #Myeloma Paper Of The Day. Warm regards!

[Surbhi Sidana, MD @SurbhiSidanaMD]

#ASH25 US Multiple Myeloma Immunotherapy consortium

We presented 14 orals, 8 posters at ASH!

Now with 25+ sites

Could never have imagined this success when Dr Hansen, Patel and I co-founded this 4+ years ago.

Incredible collaborative effort!! A lot of work goes into this.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASHkudos to @SLentzsch

This is the nicest and most succinct explanation I’ve seen for CAR-T before bsAbs in myeloma 👏

And I agree! Even once MajesTEC-3 approved based on #ASH25 results, please make sure #MMsm pts hear about BCMA CAR-T as an option before starting bsAbs!

[damian.mikulski @dmikulskimd]

@MDAndersonNews @Myeloma_Doc Congratulations @Myeloma_Doc !

[Empire State Building Observation Deck @EmpireStateBldg]

For Poland

[Robert Z. Orlowski @Myeloma_Doc]

FDA approves daratumumab for high-risk smoldering #myeloma
https://t.co/xWzKQlObDf